An experimental treatment being developed by Syntara improved movement in people at high risk of developing Parkinson's disease, and the benefit held for three months after treatment stopped, according to new results from a Phase 2 trial. …
Syntara drug candidate slows motor decline in people at high risk of Parkinson's
October 7, 2026 Australian Biotech
Latest Video
New Stories
-
Company rebates fall for the first time in years, lifting net PBS costs
October 27, 2026 - - Latest News -
Access delayed - the stakes are high for the industry's next agreements
October 27, 2026 - - Latest News -
Services Australia annual report confirms decline in prescription volume
October 27, 2026 - - Latest News -
CSL announces new chair as Brian McNamee prepares to bow out
October 26, 2026 - - Latest News -
Documents reveal net PBS spending set to remain on life support to the end of decade
October 26, 2026 - - Latest News -
PBS share of health spending on track to halve as Canberra prepares to negotiate with industry
October 26, 2026 - - Latest News -
There is an urgent need to reconsider the question of PBS sustainability
October 26, 2026 - - Latest News